|
1
|
Gourgiotis S, Kocher HM, Solaini L,
Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J
Surg. 196:252–264. 2008. View Article : Google Scholar
|
|
2
|
Zhu AX, Hong TS, Hezel AF and Kooby DA:
Current management of gallbladder carcinoma. Oncologist.
15:168–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Valle J, Wasan H, Palmer DH, et al:
Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hollebecque A, Bouche O, Romano O, et al:
Experience of gemcitabine plus oxaliplatin chemotherapy in patients
with advanced biliary tract carcinoma. Chemotherapy. 56:234–238.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Andre T, Reyes-Vidal JM, Fartoux L, et al:
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a
phase II study. Br J Cancer. 99:862–867. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu CP, Calcagno AM and Ambudkar SV:
Reversal of ABC drug transporter-mediated multidrug resistance in
cancer cells: evaluation of current strategies. Curr Mol Pharmacol.
1:93–105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cao L, Duchrow M, Windhovel U, Kujath P,
Bruch HP and Broll R: Expression of MDR1 mRNA and encoding
P-glycoprotein in archival formalin-fixed paraffin-embedded gall
bladder cancer tissues. Eur J Cancer. 34:1612–1617. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang W, Sun YP, Huang XZ, et al: Emodin
enhances sensitivity of gallbladder cancer cells to platinum drugs
via glutathion depletion and MRP1 downregulation. Biochem
Pharmacol. 79:1134–1140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aust S, Obrist P, Jaeger W, et al:
Subcellular localization of the ABCG2 transporter in normal and
malignant human gallbladder epithelium. Lab Invest. 84:1024–1036.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suzuki T, Nishio K and Tanabe S: The MRP
family and anticancer drug metabolism. Curr Drug Metab. 2:367–377.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang K, Mack P and Wong KP:
Glutathione-related mechanisms in cellular resistance to anticancer
drugs. Int J Oncol. 12:871–882. 1998.PubMed/NCBI
|
|
12
|
Huang XZ, Wang J, Huang C, et al: Emodin
enhances cytotoxicity of chemotherapeutic drugs in prostate cancer
cells: the mechanisms involve ROS-mediated suppression of multidrug
resistance and hypoxia inducible factor-1. Cancer Biol Ther.
7:468–475. 2008. View Article : Google Scholar
|
|
13
|
Wang W, Sun Y, Li X, et al: Emodin
potentiates the anticancer effect of cisplatin on gallbladder
cancer cells through the generation of reactive oxygen species and
the inhibition of survivin expression. Oncol Rep. 26:1143–1148.
2011.
|
|
14
|
Quan ZW, Yang Y, Li JY, Gong W, Qin YY and
Li SG: The mechanisms of somatostatin induced enhanced
chemosensitivity of gallbladder cancer cell line to doxorubicin:
cell cycle modulation plus target enzyme up-regulation. Biomed
Pharmacother. 64:451–457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun
W: Norcantharidin: a potential antiangiogenic agent for gallbladder
cancers in vitro and in vivo. Int J Oncol.
40:1501–1514. 2012.PubMed/NCBI
|
|
16
|
Ikeda H, Nakano G, Nagashima K, et al:
Verapamil enhancement of antitumor effect of
cis-diamminedichloroplatinum(II) in nude mouse-grown human
neuroblastoma. Cancer Res. 47:231–234. 1987.PubMed/NCBI
|
|
17
|
Wang J, Wang H, Zhao L, et al:
Down-regulation of P-glycoprotein is associated with resistance to
cisplatin and VP-16 in human lung cancer cell lines. Anticancer
Res. 30:3593–3598. 2010.PubMed/NCBI
|
|
18
|
Perrotton T, Trompier D, Chang XB, Di
Pietro A and Baubichon-Cortay H: (R)- and (S)-verapamil
differentially modulate the multidrug-resistant protein MRP1. J
Biol Chem. 282:31542–31548. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang XB, Hou YX and Riordan JR: ATPase
activity of purified multidrug resistance-associated protein. J
Biol Chem. 272:30962–30968. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koski A, Raki M, Nokisalmi P, et al:
Verapamil results in increased blood levels of oncolytic adenovirus
in treatment of patients with advanced cancer. Mol Ther.
20:221–229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Y, Lu Z, Fan P, et al: Clinical
efficacy of chemotherapy combined with verapamil in metastatic
colorectal patients. Cell Biochem Biophys. 61:393–398. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yi J, Yang J, He R, et al: Emodin enhances
arsenic trioxide-induced apoptosis via generation of reactive
oxygen species and inhibition of survival signaling. Cancer Res.
64:108–116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jing Y, Yang J, Wang Y, et al: Alteration
of subcellular redox equilibrium and the consequent oxidative
modification of nuclear factor kappaB are critical for anticancer
cytotoxicity by emodin, a reactive oxygen species-producing agent.
Free Radic Biol Med. 40:2183–2197. 2006. View Article : Google Scholar
|
|
24
|
Igarashi T, Izumi H, Uchiumi T, et al:
Clock and ATF4 transcription system regulates drug resistance in
human cancer cell lines. Oncogene. 26:4749–4760. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mwakigonja AR, Kaaya EE, Heiden T, et al:
Tanzanian malignant lymphomas: WHO classification, presentation,
ploidy, proliferation and HIV/EBV association. BMC Cancer.
10:3442010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mwakigonja AR, Pak F, Pyakurel P, et al:
Oral Kaposi’s sarcoma in Tanzania: presentation, immunopathology
and human herpesvirus-8 association. Oncol Rep. 17:1291–1299.
2007.
|
|
27
|
Quan Z, Gu J, Dong P, et al: Reactive
oxygen species-mediated endoplasmic reticulum stress and
mitochondrial dysfunction contribute to cirsimaritin-induced
apoptosis in human gallbladder carcinoma GBC-SD cells. Cancer Lett.
295:252–259. 2010. View Article : Google Scholar
|
|
28
|
Ding XW, Wu JH and Jiang CP: ABCG2: a
potential marker of stem cells and novel target in stem cell and
cancer therapy. Life Sci. 86:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abaan OD, Mutlu PK, Baran Y, Atalay C and
Gunduz U: Multidrug resistance mediated by MRP1 gene overexpression
in breast cancer patients. Cancer Invest. 27:201–205. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Donmez Y, Akhmetova L, Iseri OD, Kars MD
and Gunduz U: Effect of MDR modulators verapamil and promethazine
on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant
MCF-7 cells. Cancer Chemother Pharmacol. 67:823–828. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hait WN and Yang JM: The individualization
of cancer therapy: the unexpected role of p53. Trans Am Clin
Climatol Assoc. 117:85–101. 2006.PubMed/NCBI
|
|
33
|
Tazzari PL, Cappellini A, Ricci F, et al:
Multidrug resistance-associated protein 1 expression is under the
control of the phosphoinositide 3 kinase/Akt signal transduction
network in human acute myelogenous leukemia blasts. Leukemia.
21:427–438. 2007. View Article : Google Scholar
|
|
34
|
Meurette O, Lefeuvre-Orfila L, Rebillard
A, Lagadic-Gossmann D and Dimanche-Boitrel MT: Role of
intracellular glutathione in cell sensitivity to the apoptosis
induced by tumor necrosis factor {alpha}-related apoptosis-inducing
ligand/anticancer drug combinations. Clin Cancer Res. 11:3075–3083.
2005.
|
|
35
|
Cole SP, Sparks KE, Fraser K, et al:
Pharmacological characterization of multidrug resistant
MRP-transfected human tumor cells. Cancer Res. 54:5902–5910.
1994.PubMed/NCBI
|
|
36
|
Cullen KV, Davey RA and Davey MW:
Verapamil-stimulated glutathione transport by the multidrug
resistance-associated protein (MRP1) in leukaemia cells. Biochem
Pharmacol. 62:417–424. 2001. View Article : Google Scholar
|
|
37
|
Barattin R, Perrotton T, Trompier D, et
al: Iodination of verapamil for a stronger induction of death,
through GSH efflux, of cancer cells overexpressing MRP1. Bioorg Med
Chem. 18:6265–6274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Trompier D, Chang XB, Barattin R, du
Moulinet D’Hardemare A, Di Pietro A and Baubichon-Cortay H:
Verapamil and its derivative trigger apoptosis through glutathione
extrusion by multidrug resistance protein MRP1. Cancer Res.
64:4950–4956. 2004. View Article : Google Scholar : PubMed/NCBI
|
